JAK Inhibitors for Alopecia Areata: New Results

For decades, alopecia areata had no FDA-approved systemic treatment. Dermatologists relied on off-label corticosteroids, topical immunotherapy, and hope. That changed in June 2022 when the FDA approved baricitinib (Olumiant, Eli Lilly) for severe alopecia areata in adults. One year later, in June 2023, ritlecitinib (Litfulo, Pfizer) became the second approved option, extending eligibility to adolescents aged 12 and older. Both drugs belong to a class called JAK inhibitors, and they represent the most significant advancement in alopecia areata treatment in decades. The clinical trial data is substantial, the mechanism is well understood, and real patients are seeing hair regrow after years of bare scalp. But these are serious medications with real side effects, ongoing monitoring requirements, and costs that can reach $3,000 per month without insurance. This article breaks down the evidence, explains who qualifies, and covers how to track your response if you start treatment.

Track your alopecia areata regrowth with consistent photo checkpoints

HairLossTracker helps you document patch size, regrowth progress, and treatment response over time so you and your dermatologist have objective data at every visit.

Use the BaldingAI hair tracking app to save one baseline session now, compare monthly checkpoints later, and keep one clear record for your next treatment or dermatologist decision.

Start Tracking In BaldingAITry free tools or compare the app first

What are JAK inhibitors?

JAK stands for Janus kinase, a family of enzymes inside cells that relay signals from cytokines (inflammatory messenger molecules) on the cell surface to the cell's nucleus. When a cytokine like interferon-gamma binds to a receptor on a T-cell or hair follicle cell, JAK enzymes activate inside the cell and trigger a cascade called the JAK-STAT pathway. This cascade tells the cell to produce inflammatory proteins, recruit more immune cells, or change its behavior.

JAK inhibitors are small molecules that block these enzymes, interrupting the inflammatory signal before it reaches the nucleus. By dampening the signaling cascade, they reduce the immune system's ability to sustain an autoimmune attack. They were originally developed for rheumatoid arthritis and myelofibrosis, but researchers noticed that patients with concurrent alopecia areata were regrowing hair as a side effect. That observation, first reported by Craiglow and King at Yale in 2014 (Journal of Investigative Dermatology), launched the formal clinical trial programs that led to FDA approvals.

How JAK inhibitors work in alopecia areata specifically

Alopecia areata is driven by CD8+ T-cells that lose tolerance for hair follicle antigens and attack the follicle bulb during the anagen (growth) phase. These T-cells are recruited and activated by specific cytokines, primarily interferon-gamma and interleukin-15 (IL-15). Both of these cytokines signal through JAK enzymes. Interferon-gamma uses JAK1 and JAK2. IL-15 uses JAK1 and JAK3.

By blocking JAK1 (which is common to both pathways), a JAK inhibitor cuts off the two main signals that drive the immune attack on follicles. The T-cells are still present, but they lose the activation signal that keeps them attacking. The follicle's immune privilege is effectively restored, and the follicle can re-enter anagen and begin producing hair again. This is why JAK inhibitors can produce visible regrowth in weeks to months, even in patients who have been completely bald for years. The follicles were never destroyed, just suppressed. Remove the suppressive signal, and they resume growing.

This mechanism is specific to autoimmune hair loss. In androgenetic alopecia (pattern baldness), the problem is DHT-driven follicle miniaturization, not an immune attack. JAK inhibitors do not block DHT, do not reverse miniaturization, and have shown no benefit for pattern baldness in any published study. If your hair loss follows a pattern of gradual thinning at the temples and crown, JAK inhibitors are not the right treatment. They are exclusively for alopecia areata and related autoimmune forms.

Baricitinib (Olumiant): the BRAVE-AA1 trial

Baricitinib inhibits JAK1 and JAK2. The pivotal trial, BRAVE-AA1, was published by King et al. in the New England Journal of Medicine in 2022. It enrolled 654 adults with severe alopecia areata (50% or greater scalp hair loss for at least 6 months) and randomized them to baricitinib 4mg, baricitinib 2mg, or placebo once daily.

The primary endpoint was the percentage of patients achieving a SALT score of 20 or less at 36 weeks. SALT stands for Severity of Alopecia Tool and ranges from 0 (no hair loss) to 100 (complete scalp hair loss). A SALT score of 20 or less means 80% or greater scalp hair coverage, which is clinically meaningful. Results at 36 weeks: 39% of patients on baricitinib 4mg achieved SALT 20 or less, compared to 23% on baricitinib 2mg and 6% on placebo. The companion trial, BRAVE-AA2, replicated these findings with similar response rates.

For patients who did not respond by 36 weeks, extended data showed continued improvement through 52 weeks, suggesting that response accumulates over time. Some patients who appeared to be non-responders at 6 months became responders by 12 months. This has practical implications for how long you should track before concluding the drug isn't working.

Ritlecitinib (Litfulo): the ALLEGRO trial

Ritlecitinib is a selective JAK3 and TEC family kinase inhibitor developed by Pfizer. It targets a narrower set of kinases than baricitinib, which theoretically may produce fewer off-target effects. The ALLEGRO-2b/3 trial enrolled patients aged 12 and older with 50% or greater scalp hair loss.

At 24 weeks, 23% of patients on ritlecitinib 50mg achieved SALT 20 or less, compared to 1.6% on placebo. Extended data through 48 weeks showed the response rate climbing to approximately 40%. The approval for adolescents aged 12 and older was significant because alopecia areata frequently begins in childhood and adolescence, and no prior FDA-approved systemic option existed for this age group. The emotional and social impact of alopecia areata in teenagers is particularly severe, making an approved treatment option meaningful beyond the numbers.

Comparing the two approved drugs

No head-to-head trial has directly compared baricitinib and ritlecitinib. Cross-trial comparisons are unreliable because the study populations, duration, and endpoints differ. That said, some practical differences exist. Baricitinib at 4mg showed a 39% response rate at 36 weeks. Ritlecitinib at 50mg showed 23% at 24 weeks, rising to approximately 40% at 48 weeks. Both ultimately reach similar territory with extended treatment. Ritlecitinib's approval for ages 12 and older gives it a distinct advantage for adolescent patients. Baricitinib is approved only for adults.

Your dermatologist will consider your age, severity, medical history, insurance coverage, and side effect profile when recommending one over the other. Neither drug is clearly superior based on current data. The most important factor is whether you respond at all, and that can only be determined by starting treatment and tracking your SALT score over time.

Side effects and monitoring requirements

JAK inhibitors are immunomodulatory drugs that affect multiple inflammatory pathways beyond the ones involved in alopecia areata. This broad activity produces a side effect profile that requires ongoing monitoring. Common side effects in the BRAVE and ALLEGRO trials included upper respiratory infections (25-30% of participants), headache (10-15%), acne (6-8%), elevated cholesterol (5-10%), and urinary tract infections (5-7%). Most of these were mild to moderate and did not lead to discontinuation.

More serious concerns include an increased risk of herpes zoster (shingles), which occurred in approximately 3-5% of trial participants. Patients starting a JAK inhibitor should discuss shingles vaccination with their physician. Blood count changes, liver enzyme elevations, and lipid increases require regular laboratory monitoring, typically at baseline, 4 weeks, 12 weeks, and every 3-6 months thereafter. The FDA's boxed warning on JAK inhibitors (originally from the rheumatoid arthritis class) mentions risks of serious infections, malignancy, thrombosis, and cardiovascular events, though these were observed primarily in older patients with rheumatoid arthritis and multiple comorbidities. The alopecia areata trial populations, which tend to be younger and healthier, showed lower rates of these serious events.

Cost and access

The wholesale cost of both baricitinib and ritlecitinib runs $2,500 to $3,000 per month. Insurance coverage varies significantly. Some plans cover these drugs for alopecia areata; others classify alopecia areata as cosmetic and deny coverage. Both manufacturers offer patient assistance programs and copay cards that can reduce out-of-pocket costs substantially for eligible patients. Your dermatologist's office can typically help navigate prior authorization and appeals if initial coverage is denied. The cost consideration is relevant to tracking because these drugs require ongoing use, and stopping them typically leads to relapse. You are committing to a long-term medication and its associated costs.

Does hair fall out again if you stop?

In most cases, yes. Extension studies from both BRAVE and ALLEGRO trials showed that patients who discontinued the drug after achieving regrowth experienced recurrence of hair loss within 3-6 months. This is consistent with the drug's mechanism: it suppresses the immune attack but does not cure the underlying autoimmune condition. Once the suppressive effect is removed, T-cells can resume their attack on follicles. Some patients in the trials maintained partial regrowth after discontinuation, but complete, durable remission after stopping was uncommon. Current evidence supports treating JAK inhibitors for alopecia areata as a maintenance therapy, not a short-term course.

How to track your response

The clinical trials used the SALT scoring system, and you can approximate this at home. SALT divides the scalp into four quadrants (top 40%, back 24%, right side 18%, left side 18%) and estimates the percentage of hair loss in each area. The total gives a score from 0 to 100. You don't need to calculate exact SALT scores at home, but the principle is useful: photograph each area of your scalp at consistent angles and lighting, and estimate coverage percentage.

Baseline documentation. Before starting your JAK inhibitor, photograph all affected areas. Include close-ups of individual patches and a wide-angle top-down view. Note the approximate diameter and location of each patch. This baseline is essential because regrowth may be subtle in the first 8-12 weeks, and without a clear "before" reference, you may not recognize early progress.

Monthly photo checkpoints. Take comparison photos every 4 weeks. Look for vellus hair (fine, light, short hairs) appearing within previously bare patches. Vellus regrowth is the first sign the drug is working. Over subsequent weeks, these vellus hairs should darken, thicken, and lengthen into terminal hairs. Track which patches respond first and which remain resistant, as this information helps your dermatologist adjust the treatment plan.

Timeline expectations. Based on trial data, expect the following rough timeline: weeks 4-8 for first visible vellus regrowth, weeks 12-16 for noticeable coverage improvement, weeks 24-36 for maximal response on the initial assessment, and continued improvement possible through week 52. If you see no regrowth by 24 weeks, discuss dose adjustment or switching drugs with your dermatologist. Do not conclude failure before that point.

For a deeper understanding of the hair growth cycle phases and why regrowth takes time even when the drug is working, review our guide on anagen, catagen, and telogen. Understanding the cycle helps set realistic expectations for how quickly full-thickness regrowth can occur. You can begin documenting your recovery using the autoimmune recovery tracking template.

For more on alopecia areata itself, including how to distinguish it from pattern baldness and track patch evolution, see our hair loss tracking blog.

Frequently asked questions

Are JAK inhibitors a cure for alopecia areata?

No. JAK inhibitors suppress the autoimmune attack on hair follicles, but they do not eliminate the underlying autoimmune condition. They are a maintenance therapy. In clinical trials, most patients who discontinued the drug experienced hair loss recurrence within 3-6 months. Current evidence supports ongoing treatment to maintain regrowth, similar to how blood pressure medication controls hypertension without curing it.

How long do JAK inhibitors take to work for hair loss?

Most responders see initial vellus hair regrowth within 8-12 weeks. Meaningful cosmetic improvement typically appears by 16-24 weeks. In the BRAVE-AA1 trial, the primary endpoint was measured at 36 weeks, and some patients continued improving through 52 weeks. Your dermatologist will generally recommend at least 6 months of treatment before evaluating whether the drug is working for you.

What are the side effects of baricitinib for hair?

The most common side effects in trials were upper respiratory infections (25-30%), headache (10-15%), elevated cholesterol (5-10%), acne (6-8%), and urinary tract infections (5-7%). Herpes zoster (shingles) occurred in 3-5% of participants. Regular blood monitoring for blood counts, liver enzymes, and lipids is required. Serious events like major infections and thrombosis were rare in the alopecia areata trial population.

Does hair fall out again if you stop JAK inhibitors?

In most cases, yes. Extension data from both baricitinib and ritlecitinib trials showed that patients who stopped treatment experienced recurrence of hair loss, typically within 3-6 months. Some patients retained partial regrowth, but complete durable remission after discontinuation was uncommon. This means JAK inhibitors for alopecia areata are currently a long-term commitment rather than a short course that produces permanent results.